CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 719 enrolled
Drug / intervention
Pioglitazone +1 moredrug
Likely dose
Pioglitazone 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00331487
NCT00331487Phase 3Completed
CompareCT.gov

Pioglitazone Versus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

Takeda·interventional·Posted May 31, 2006·Updated Feb 28, 2012

In Brief

A Phase 3 clinical trial evaluating Pioglitazone and Rosiglitazone for Diabetes Mellitus. Completed, enrolled 719 participants across 67 sites.

Detailed Summary

Efficacy comparison of Pioglitazone, once daily (QD), to Rosiglitazone in participants with Type 2 Diabetes

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 31, 2006
Enrollment StartSep 1, 2000
Primary CompletionMar 1, 2004
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 20.1 years ago

Interventions

Pioglitazonedrug

Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks

Rosiglitazonedrug

Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks